Jacobs Levy Equity Management Inc. Sells 135,268 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Jacobs Levy Equity Management Inc. trimmed its position in shares of Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 65.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 72,625 shares of the company's stock after selling 135,268 shares during the period. Jacobs Levy Equity Management Inc. owned 0.14% of Sight Sciences worth $264,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. KCK LTD. purchased a new stake in Sight Sciences during the fourth quarter valued at about $15,925,000. Long Focus Capital Management LLC raised its position in Sight Sciences by 158.8% during the fourth quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company's stock valued at $8,149,000 after purchasing an additional 1,373,535 shares in the last quarter. Geode Capital Management LLC raised its position in Sight Sciences by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 792,860 shares of the company's stock valued at $2,887,000 after purchasing an additional 8,731 shares in the last quarter. B Group Inc. purchased a new position in shares of Sight Sciences in the fourth quarter worth about $2,291,000. Finally, D. E. Shaw & Co. Inc. increased its holdings in shares of Sight Sciences by 27.6% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 410,325 shares of the company's stock worth $1,494,000 after buying an additional 88,738 shares during the period. 55.51% of the stock is owned by institutional investors.

Sight Sciences Stock Performance

SGHT traded down $0.05 during mid-day trading on Friday, reaching $3.23. 21,513 shares of the company traded hands, compared to its average volume of 213,776. The stock has a market capitalization of $166.98 million, a P/E ratio of -3.17 and a beta of 2.41. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The company's fifty day moving average price is $2.82 and its 200-day moving average price is $3.13. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $8.45.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. On average, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Insider Buying and Selling at Sight Sciences

In related news, CEO Paul Badawi sold 24,174 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now owns 6,010,580 shares of the company's stock, valued at approximately $13,824,334. This trade represents a 0.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Manohar K. Raheja purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the acquisition, the executive vice president now owns 145,000 shares in the company, valued at $395,850. The trade was a 7.41% increase in their position. The disclosure for this purchase can be found here. Insiders sold 35,196 shares of company stock valued at $81,001 in the last 90 days. Insiders own 30.90% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on SGHT shares. Stifel Nicolaus decreased their price objective on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Citigroup reiterated a "neutral" rating and issued a $3.60 price objective (up previously from $3.20) on shares of Sight Sciences in a report on Thursday. Lake Street Capital lifted their price objective on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday, May 9th. Finally, UBS Group decreased their price objective on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a report on Monday, January 27th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Sight Sciences has a consensus rating of "Hold" and a consensus target price of $4.02.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.